COMMUNIQUÉS West-GlobeNewswire

CAPS® Teams with Kit Check to Add Serialized Radio Frequency Identification (RFID) Tags on Pre-Filled Syringes
03/12/2018
BETHLEHEM, Pa., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS) has announced a collaborative agreement to embed Kit Check’s serialized RFID tags on CAPS’ pre-filled anesthesia [...]
Exeter Hospital joins North American Partners in Anesthesia
03/12/2018
MELVILLE, N.Y., Dec. 03, 2018 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA) , one of the leading single-specialty anesthesia and perioperative management companies in the US, recently expanded [...]
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
03/12/2018
- New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) - CAD patients treated with APL-2 had an improvement in [...]
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
03/12/2018
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO, Switzerland and San [...]
NICOX : Number of voting rights as of November 30. 2018
03/12/2018
Nicox SA Société anonyme with a registered capital of € 29,715,320 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On December 3, 2018, MONTHLY PUBLICATION OF THE [...]
NICOX : Nombre de droits de vote au 30 novembre 2018
03/12/2018
Nicox SA Société anonyme au capital de 29 715 320 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 3 décembre 2018, PUBLICATION MENSUELLE DU NOMBRE D' [...]
Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors
03/12/2018
- Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda ® (Pembrolizumab) in Hodgkin Lymphoma [...]
Ossur Hf : Transactions in relation to share buyback program
03/12/2018
Announcement no. 69/2018 3 December 2018 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]
Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)
03/12/2018
– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) of 57.6% in Newly Diagnosed AML Patients Ineligible for Standard Treatment – – Supplemental New Drug Application for Single [...]
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
03/12/2018
Preclinical Data Supports Advancement of ALLO-715 into Phase 1 in Multiple Myeloma ALLO-715 Investigational New Drug Application and Initiation of a Phase 1 Trial Planned for 2019 SOUTH SAN FRANCISCO, Calif., Dec. 03, [...]
Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation
03/12/2018
– 91% CR+CRi/CRp Rate in Ivosidenib-treated Patients with De Novo AML and 53% in Ivosidenib-treated Patients with Secondary AML – – 77% CR+CRi/CRp Rate in Enasidenib-treated Patients with De Novo AML and 64% in [...]
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
03/12/2018
Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable Safety in Pediatric [...]
Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial
03/12/2018
Study Will Evaluate Simultaneous Use of Radiofrequency and Cryo Surgical Ablation Devices in Cardiac Surgery Patients with Atrial Fibrillation DUBLIN - December 3, 2018 - Medtronic plc (NYSE:MDT) today announced the [...]
Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy
03/12/2018
Company changes name to Outlook Therapeutics, Inc.; ticker symbol to “OTLK” Jeff Evanson joins team as Chief Commercial Officer Terry Dagnon joins team as Chief Operating Officer Closed second tranche of private [...]
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
03/12/2018
Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo Clinically Meaningful [...]
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
03/12/2018
Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019 NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient [...]
Golden Leaf Holdings favorably restructures deal terms with Tahoe Hydroponics
03/12/2018
PORTLAND, Ore., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around [...]
Eve & Co Provides Update on Phase 2 Expansion
03/12/2018
TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (TSX-V: EVE) (“Eve & Co” or the “Company”) is pleased to provide an update on its 780,000 square foot greenhouse expansion. The construction of [...]
TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
03/12/2018
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, [...]

Pages